Dry Age-Related Macular Degeneration Market Trends and Overview

Dry Age-Related Macular Degeneration Market Size was valued at USD 11.12 billion in 2022. It is projected to reach USD 20.92 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.22% during the forecast period from 2023 to 2030.

Dry AMD, a prevalent eye disease primarily affecting older individuals, has garnered significant attention due to its impact on vision and quality of life. With the aging population and increasing prevalence of AMD, the market for dry AMD treatments and therapies is expected to witness substantial growth in the coming years.

The projected market value of USD 20.92 billion by 2030 reflects the growing demand for effective interventions and advancements in medical technology. This upward trajectory can be attributed to the rising awareness among patients, healthcare professionals, and regulatory bodies regarding the importance of early diagnosis and treatment of dry AMD.

Furthermore, the market growth is fueled by ongoing research and development activities aimed at discovering innovative therapies and interventions. Pharmaceutical companies and biotechnology firms are actively investing in clinical trials and studies to develop novel drugs and therapies that can effectively manage and potentially reverse the progression of dry AMD.

Moreover, technological advancements in diagnostic tools and imaging techniques have significantly improved the early detection and monitoring of dry AMD. This has led to a higher rate of diagnosis and subsequent treatment initiation, further driving the market growth.

In conclusion, the Dry Age-Related Macular Degeneration market is poised for substantial growth, with a projected value of USD 20.92 billion by 2030. The increasing prevalence of AMD, coupled with advancements in medical technology and ongoing research efforts, are key factors contributing to this growth. As the market expands, it is crucial for stakeholders to collaborate and invest in innovative solutions to address the unmet needs of patients and improve their quality of life.

Get Free Sample Report @ https://www.snsinsider.com/sample-request/2627

KEY MARKET SEGMENTATION:

By Stages

  • Early AMD
  • Intermediate AMD
  • Late AMD

By End User

  • Hospitals & Clinics
  • Diagnostic Centers
  • Academic Research Institutes
  • Others

By Age Group

  • Above 40 Years
  • Above 60 Years
  • Above 75 Years

By Diagnosis & Treatment

  • Treatment
  • Diagnosis

By Route of Administration

  • Oral
  • Injectables

Major Players Listed in the Report are as Follows:

Santen Pharmaceuticals Inc., Ocumension Therapeutics Co. Ltd, Iveric Bio, Eyestem Research Pvt Ltd, Allergan plc, Bausch Health, Belite Bio Inc., Kubota Vision Inc., Alimera Science Inc., Phio Pharmaceuticals Corp,Yuyang DNU Co., Ltd, Stealth Biotherapeutics Inc. and other players.

About US:

SNS Insider has been a leader in data and analytics globally with its authentic consumer and market insights. The trust of our clients and business partners has always been at the center of who we are as a company. We are a business that leads the industry in innovation, and to support the success of our clients, our highly skilled engineers, consultants, and data scientists have consistently pushed the limits of the industry with innovative methodology and measuring technologies.

We assist our clients to anticipate industrial, economic, and consumer trends to drive disruptive change by fusing global experience with local information from experts throughout the world. We bring context to strategic and tactical data by bridging approaches based on data science and field research, assisting you in addressing your most pressing problems and spotting possibilities.

Contact Us:

Akash Anand – Head of Business Development & Strategy,

info@snsinsider.com,

Phone: +1-415-230-0044 (US) | +91-7798602273 (IND),

Website: https://www.snsinsider.com